دورية أكاديمية

1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)

التفاصيل البيبلوغرافية
العنوان: 1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)
المؤلفون: Felip, E., Srivastava, M., Reck, M., Wakelee, H., Altorki, N.K., Vallieres, E., Liersch, R., Harada, M., Tanaka, H., Hamm, J.T., McCune, S., Bennett, E., Gitlitz, B.J., McNally, V.A., Novello, S., Ballinger, M., Zou, W., Nabet, B., Das Thakur, M., Zhou, C.
المصدر: In Immuno-Oncology and Technology December 2022 16 Supplement 1
قاعدة البيانات: ScienceDirect
الوصف
تدمد:25900188
DOI:10.1016/j.iotech.2022.100106